sur Theranexus (EPA:ALTHX)
Publication of the letter to shareholders by Theranexus
On January 8, 2026, Theranexus, a biopharmaceutical company based in Lyon, announced the publication of its letter to shareholders. Specializing in rare neurological diseases, the company continues to share key information about its activities and outlook.
This recently published letter is available on the Theranexus website in the shareholders' section. The company invites its investors to subscribe to receive all its communications.
Theranexus operates in the field of rare diseases with two flagship drugs: TX01 for Niemann-Pick type C disease and Gaucher disease, and Batten-1 for Batten disease. The company is also developing an innovative antisense oligonucleotide platform.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus